Elimination of Piperacillin and Tazobactam by Renal Replacement Therapies with AN69 and Polysulfone Hemofilters: Evaluation of the Sieving Coefficient
Background/Aim: Piperacillin-tazobactam is commonly used to treat infections in ICU patients. Controversial data have been published about the sieving/saturation coefficient (Sc/Sa) of piperacillin during continuous renal replacement therapies (CRRT). The objective was to evaluate the Sc/Sa of piper...
Gespeichert in:
| Veröffentlicht in: | Blood purification 2006-01, Vol.24 (4), p.347-354 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 354 |
|---|---|
| container_issue | 4 |
| container_start_page | 347 |
| container_title | Blood purification |
| container_volume | 24 |
| creator | Arzuaga, A. Isla, A. Gascón, A.R. Maynar, J. Corral, E. Pedraz, J.L. |
| description | Background/Aim: Piperacillin-tazobactam is commonly used to treat infections in ICU patients. Controversial data have been published about the sieving/saturation coefficient (Sc/Sa) of piperacillin during continuous renal replacement therapies (CRRT). The objective was to evaluate the Sc/Sa of piperacillin-tazobactam during continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodialysis (CVVHD) using AN69 and polysulfone. Methods: Ringer lactate, BSA-containing Ringer lactate and plasma were circulated at 150 ml/min. The ultrafiltrate/dialysis flow was kept at 1,500 ml/min. A bolus was injected and samples were taken. Drugs were measured using HPLC. Sc/Sa was calculated according to standard formula. Results: Free passage of drugs through the membranes was reported with protein free solutions. In the presence of proteins the Sc/Sa lowered and correlated to protein free fraction. Polysulfone had a significantly higher permeability than AN69 during CVVH. Conclusion: Drug binding to albumin contributes to the decrease of the Sc/Sa of piperacillin but it does not completely justify the in vivo value obtained by some authors. |
| doi_str_mv | 10.1159/000092921 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_18017347</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16645266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c333t-2d72ab90c39523bb8b2183037729b74821a7554106bdd80f68abee00cb6da0063</originalsourceid><addsrcrecordid>eNpF0E1vEzEQBmALgWgoHDgjIV964LDgj7V3za2KQotUQQXhHI2948bg9a7sTVH4IfxetiRK5zBzeWZGegl5zdl7zpX5wOYywgj-hCx4LXhlGqmekgUTSlaK6faMvCjlJ2O81so8J2dc61oJrRfk7yqGPiSYwpDo4OltGDGDCzGGRCF1dA1_Bgtugp7aPf2GCeLcxwgOe0wTXW9nPwYs9HeYtvTyizb_926HuC-76IeE9Br7wYc4YS4f6eoe4u70b9oi_R7wPqQ7uhzQ--DCfPYleeYhFnx1nOfkx6fVenld3Xy9-ry8vKmclHKqRNcIsIY5aZSQ1rZW8FYy2TTC2KZuBYdGqZozbbuuZV63YBEZc1Z3wJiW5-Td4a7LQykZ_WbMoYe833C2ech2c8p2tm8PdtzZHrtHeQxzBhdHAMVB9BmSC-XRtYw3sm5m9-bgfkG-w3wChzf_AMmgiwI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Elimination of Piperacillin and Tazobactam by Renal Replacement Therapies with AN69 and Polysulfone Hemofilters: Evaluation of the Sieving Coefficient</title><source>MEDLINE</source><source>Karger Journals</source><creator>Arzuaga, A. ; Isla, A. ; Gascón, A.R. ; Maynar, J. ; Corral, E. ; Pedraz, J.L.</creator><creatorcontrib>Arzuaga, A. ; Isla, A. ; Gascón, A.R. ; Maynar, J. ; Corral, E. ; Pedraz, J.L.</creatorcontrib><description>Background/Aim: Piperacillin-tazobactam is commonly used to treat infections in ICU patients. Controversial data have been published about the sieving/saturation coefficient (Sc/Sa) of piperacillin during continuous renal replacement therapies (CRRT). The objective was to evaluate the Sc/Sa of piperacillin-tazobactam during continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodialysis (CVVHD) using AN69 and polysulfone. Methods: Ringer lactate, BSA-containing Ringer lactate and plasma were circulated at 150 ml/min. The ultrafiltrate/dialysis flow was kept at 1,500 ml/min. A bolus was injected and samples were taken. Drugs were measured using HPLC. Sc/Sa was calculated according to standard formula. Results: Free passage of drugs through the membranes was reported with protein free solutions. In the presence of proteins the Sc/Sa lowered and correlated to protein free fraction. Polysulfone had a significantly higher permeability than AN69 during CVVH. Conclusion: Drug binding to albumin contributes to the decrease of the Sc/Sa of piperacillin but it does not completely justify the in vivo value obtained by some authors.</description><identifier>ISSN: 0253-5068</identifier><identifier>EISSN: 1421-9735</identifier><identifier>DOI: 10.1159/000092921</identifier><identifier>PMID: 16645266</identifier><identifier>CODEN: BLPUDO</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Acrylic Resins - adverse effects ; Acrylonitrile - adverse effects ; Acrylonitrile - analogs & derivatives ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Anti-Bacterial Agents - pharmacokinetics ; Biocompatible Materials - adverse effects ; Biological and medical sciences ; Critical Care ; Drug Therapy, Combination ; Emergency and intensive care: renal failure. Dialysis management ; Hemofiltration - adverse effects ; Hemofiltration - instrumentation ; Humans ; In Vitro Techniques ; Intensive care medicine ; Medical sciences ; Membranes, Artificial ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Original Paper ; Penicillanic Acid - analogs & derivatives ; Penicillanic Acid - pharmacokinetics ; Piperacillin - pharmacokinetics ; Polymers - adverse effects ; Renal failure ; Statistics, Nonparametric ; Sulfones - adverse effects</subject><ispartof>Blood purification, 2006-01, Vol.24 (4), p.347-354</ispartof><rights>2006 S. Karger AG, Basel</rights><rights>2006 INIST-CNRS</rights><rights>Copyright 2006 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c333t-2d72ab90c39523bb8b2183037729b74821a7554106bdd80f68abee00cb6da0063</citedby><cites>FETCH-LOGICAL-c333t-2d72ab90c39523bb8b2183037729b74821a7554106bdd80f68abee00cb6da0063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18017347$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16645266$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arzuaga, A.</creatorcontrib><creatorcontrib>Isla, A.</creatorcontrib><creatorcontrib>Gascón, A.R.</creatorcontrib><creatorcontrib>Maynar, J.</creatorcontrib><creatorcontrib>Corral, E.</creatorcontrib><creatorcontrib>Pedraz, J.L.</creatorcontrib><title>Elimination of Piperacillin and Tazobactam by Renal Replacement Therapies with AN69 and Polysulfone Hemofilters: Evaluation of the Sieving Coefficient</title><title>Blood purification</title><addtitle>Blood Purif</addtitle><description>Background/Aim: Piperacillin-tazobactam is commonly used to treat infections in ICU patients. Controversial data have been published about the sieving/saturation coefficient (Sc/Sa) of piperacillin during continuous renal replacement therapies (CRRT). The objective was to evaluate the Sc/Sa of piperacillin-tazobactam during continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodialysis (CVVHD) using AN69 and polysulfone. Methods: Ringer lactate, BSA-containing Ringer lactate and plasma were circulated at 150 ml/min. The ultrafiltrate/dialysis flow was kept at 1,500 ml/min. A bolus was injected and samples were taken. Drugs were measured using HPLC. Sc/Sa was calculated according to standard formula. Results: Free passage of drugs through the membranes was reported with protein free solutions. In the presence of proteins the Sc/Sa lowered and correlated to protein free fraction. Polysulfone had a significantly higher permeability than AN69 during CVVH. Conclusion: Drug binding to albumin contributes to the decrease of the Sc/Sa of piperacillin but it does not completely justify the in vivo value obtained by some authors.</description><subject>Acrylic Resins - adverse effects</subject><subject>Acrylonitrile - adverse effects</subject><subject>Acrylonitrile - analogs & derivatives</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Biocompatible Materials - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Critical Care</subject><subject>Drug Therapy, Combination</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Hemofiltration - adverse effects</subject><subject>Hemofiltration - instrumentation</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Intensive care medicine</subject><subject>Medical sciences</subject><subject>Membranes, Artificial</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Original Paper</subject><subject>Penicillanic Acid - analogs & derivatives</subject><subject>Penicillanic Acid - pharmacokinetics</subject><subject>Piperacillin - pharmacokinetics</subject><subject>Polymers - adverse effects</subject><subject>Renal failure</subject><subject>Statistics, Nonparametric</subject><subject>Sulfones - adverse effects</subject><issn>0253-5068</issn><issn>1421-9735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1vEzEQBmALgWgoHDgjIV964LDgj7V3za2KQotUQQXhHI2948bg9a7sTVH4IfxetiRK5zBzeWZGegl5zdl7zpX5wOYywgj-hCx4LXhlGqmekgUTSlaK6faMvCjlJ2O81so8J2dc61oJrRfk7yqGPiSYwpDo4OltGDGDCzGGRCF1dA1_Bgtugp7aPf2GCeLcxwgOe0wTXW9nPwYs9HeYtvTyizb_926HuC-76IeE9Br7wYc4YS4f6eoe4u70b9oi_R7wPqQ7uhzQ--DCfPYleeYhFnx1nOfkx6fVenld3Xy9-ry8vKmclHKqRNcIsIY5aZSQ1rZW8FYy2TTC2KZuBYdGqZozbbuuZV63YBEZc1Z3wJiW5-Td4a7LQykZ_WbMoYe833C2ech2c8p2tm8PdtzZHrtHeQxzBhdHAMVB9BmSC-XRtYw3sm5m9-bgfkG-w3wChzf_AMmgiwI</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>Arzuaga, A.</creator><creator>Isla, A.</creator><creator>Gascón, A.R.</creator><creator>Maynar, J.</creator><creator>Corral, E.</creator><creator>Pedraz, J.L.</creator><general>Karger</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20060101</creationdate><title>Elimination of Piperacillin and Tazobactam by Renal Replacement Therapies with AN69 and Polysulfone Hemofilters: Evaluation of the Sieving Coefficient</title><author>Arzuaga, A. ; Isla, A. ; Gascón, A.R. ; Maynar, J. ; Corral, E. ; Pedraz, J.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c333t-2d72ab90c39523bb8b2183037729b74821a7554106bdd80f68abee00cb6da0063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Acrylic Resins - adverse effects</topic><topic>Acrylonitrile - adverse effects</topic><topic>Acrylonitrile - analogs & derivatives</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Biocompatible Materials - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Critical Care</topic><topic>Drug Therapy, Combination</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Hemofiltration - adverse effects</topic><topic>Hemofiltration - instrumentation</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Intensive care medicine</topic><topic>Medical sciences</topic><topic>Membranes, Artificial</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Original Paper</topic><topic>Penicillanic Acid - analogs & derivatives</topic><topic>Penicillanic Acid - pharmacokinetics</topic><topic>Piperacillin - pharmacokinetics</topic><topic>Polymers - adverse effects</topic><topic>Renal failure</topic><topic>Statistics, Nonparametric</topic><topic>Sulfones - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arzuaga, A.</creatorcontrib><creatorcontrib>Isla, A.</creatorcontrib><creatorcontrib>Gascón, A.R.</creatorcontrib><creatorcontrib>Maynar, J.</creatorcontrib><creatorcontrib>Corral, E.</creatorcontrib><creatorcontrib>Pedraz, J.L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Blood purification</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arzuaga, A.</au><au>Isla, A.</au><au>Gascón, A.R.</au><au>Maynar, J.</au><au>Corral, E.</au><au>Pedraz, J.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elimination of Piperacillin and Tazobactam by Renal Replacement Therapies with AN69 and Polysulfone Hemofilters: Evaluation of the Sieving Coefficient</atitle><jtitle>Blood purification</jtitle><addtitle>Blood Purif</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>24</volume><issue>4</issue><spage>347</spage><epage>354</epage><pages>347-354</pages><issn>0253-5068</issn><eissn>1421-9735</eissn><coden>BLPUDO</coden><abstract>Background/Aim: Piperacillin-tazobactam is commonly used to treat infections in ICU patients. Controversial data have been published about the sieving/saturation coefficient (Sc/Sa) of piperacillin during continuous renal replacement therapies (CRRT). The objective was to evaluate the Sc/Sa of piperacillin-tazobactam during continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodialysis (CVVHD) using AN69 and polysulfone. Methods: Ringer lactate, BSA-containing Ringer lactate and plasma were circulated at 150 ml/min. The ultrafiltrate/dialysis flow was kept at 1,500 ml/min. A bolus was injected and samples were taken. Drugs were measured using HPLC. Sc/Sa was calculated according to standard formula. Results: Free passage of drugs through the membranes was reported with protein free solutions. In the presence of proteins the Sc/Sa lowered and correlated to protein free fraction. Polysulfone had a significantly higher permeability than AN69 during CVVH. Conclusion: Drug binding to albumin contributes to the decrease of the Sc/Sa of piperacillin but it does not completely justify the in vivo value obtained by some authors.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>16645266</pmid><doi>10.1159/000092921</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0253-5068 |
| ispartof | Blood purification, 2006-01, Vol.24 (4), p.347-354 |
| issn | 0253-5068 1421-9735 |
| language | eng |
| recordid | cdi_pascalfrancis_primary_18017347 |
| source | MEDLINE; Karger Journals |
| subjects | Acrylic Resins - adverse effects Acrylonitrile - adverse effects Acrylonitrile - analogs & derivatives Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Anti-Bacterial Agents - pharmacokinetics Biocompatible Materials - adverse effects Biological and medical sciences Critical Care Drug Therapy, Combination Emergency and intensive care: renal failure. Dialysis management Hemofiltration - adverse effects Hemofiltration - instrumentation Humans In Vitro Techniques Intensive care medicine Medical sciences Membranes, Artificial Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Original Paper Penicillanic Acid - analogs & derivatives Penicillanic Acid - pharmacokinetics Piperacillin - pharmacokinetics Polymers - adverse effects Renal failure Statistics, Nonparametric Sulfones - adverse effects |
| title | Elimination of Piperacillin and Tazobactam by Renal Replacement Therapies with AN69 and Polysulfone Hemofilters: Evaluation of the Sieving Coefficient |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T23%3A55%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elimination%20of%20Piperacillin%20and%20Tazobactam%20by%20Renal%20Replacement%20Therapies%20with%20AN69%20and%20Polysulfone%20Hemofilters:%20Evaluation%20of%20the%20Sieving%20Coefficient&rft.jtitle=Blood%20purification&rft.au=Arzuaga,%20A.&rft.date=2006-01-01&rft.volume=24&rft.issue=4&rft.spage=347&rft.epage=354&rft.pages=347-354&rft.issn=0253-5068&rft.eissn=1421-9735&rft.coden=BLPUDO&rft_id=info:doi/10.1159/000092921&rft_dat=%3Cpubmed_pasca%3E16645266%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16645266&rfr_iscdi=true |